# Efficacy and Safety of Toluedesvenlafaxine Hydrochloride Extended-release Tablets in Somatic Symptoms of Depression

> **NCT05849272** · PHASE4 · COMPLETED · sponsor: **Shanghai Mental Health Center** · enrollment: 60 (actual)

## Conditions studied

- Somatic Symptom

## Interventions

- **DRUG:** toludesvenlafaxine hydrochloride sustained-release tablets

## Key facts

- **NCT ID:** NCT05849272
- **Lead sponsor:** Shanghai Mental Health Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-12
- **Primary completion:** 2024-05-08
- **Final completion:** 2024-05-08
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2025-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05849272

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05849272, "Efficacy and Safety of Toluedesvenlafaxine Hydrochloride Extended-release Tablets in Somatic Symptoms of Depression". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05849272. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*